Johnson & Johnson's earnings call highlights significant challenges in the Consumer segment, primarily due to recalls and economic headwinds.  While the Pharmaceuticals and Medical Devices segments performed relatively better, management acknowledges ongoing pricing pressure and reduced procedure volumes in the medical device sector.  The guidance suggests a cautious outlook with projected moderate growth, potentially impacted by healthcare reform and price pressures.
[0]
